Thus, the aim of this study was to determine the expression of CCR5, CXCR3, and CCR4 on blood CD4+ T and CD8+ T cells from patients with NMO and MS treated with IFN-â1b (Betaferon). The gene discussed is CXCR3; the disease is myeloid sarcoma.